side effects [Magen and Gozes, 2014]. As stated above, specific cognitive abnormalities were also ameliorated by NAP in an ADNP heterozygous knockout mouse model. While these observations may raise hope for treatment in patients with ADNP mutations, it has to be noted that the mouse model has not been evaluated for autistic traits so far. Consequently, it is not known whether davunetide is able to interfere with the autistic traits. A second point of interest is that, generally speaking, drug testing in a mouse model needs independent confirmation because of the intrinsic variance associated with this type of experiments and because environmental conditions might interfere with the test result [Crabbe et al., 1999; Wahlsten et al., 2003].
